Patient‐reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment

Author:

Adesoye Taiwo1ORCID,Liao Kai‐Ping2,Peterson Susan3,Li Liang4,Zorzi Daria2,Holmes Holly M.5,Chavez‐MacGregor Mariana26ORCID,Giordano Sharon H.26

Affiliation:

1. Department of Breast Surgical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

2. Department of Health Services Research The University of Texas MD Anderson Cancer Center Houston Texas USA

3. Department of Behavioral Science, Division of Cancer Prevention and Population Sciences The University of Texas MD Anderson Cancer Center Houston Texas USA

4. Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas USA

5. Division of Geriatric and Palliative Medicine, Department of Internal Medicine University of Texas Houston McGovern Medical School Houston Texas USA

6. Department of Breast Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

Abstract

AbstractBackgroundLittle is known about long‐term treatment‐related symptoms in older breast cancer survivors. We characterized long‐term patient‐reported symptoms and examined factors associated with the presence and severity of symptoms, and symptom interference with daily activities.MethodsTexas Cancer Registry (TCR) Medicare linkage data was used to identify breast cancer patients age 65 and older with local/regional stage disease diagnosed between 2012–2013. Symptom burden was assessed using breast‐specific items from the Patient‐Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO‐CTCAE™). Demographic and clinical data also were collected. Logistic regression models were used to assess the association between symptom burden and respondent sociodemographic and clinical characteristics.ResultsOf 4448 eligible patients, 1594 (response‐rate 35.8%) completed questionnaires. Of these, 1245 eligible respondents were included in the analysis based on self‐reported data. Median time from diagnosis to survey completion was 68 months (IQR: 62–73). Most frequently reported symptoms were fatigue/lack of energy (76.8%), aching muscles (72.1%) and aching joints (72.5%). Receipt of chemotherapy was associated with higher symptom burden. Patients treated with adjuvant chemotherapy had higher risk of numbness/tingling (OR: 3.16; 95% CI: 2.36–4.24), hair loss (OR: 2.72; 95% CI: 2.05–3.60), and fatigue/lack of energy (OR: 1.80; 95% CI: 1.29–2.52). Similarly, patients who received chemotherapy were more likely to report the majority of symptoms as moderate to severe and as interfering with daily activities.ConclusionReceipt of chemotherapy is associated with significant symptom burden more than 5 years after breast cancer treatment. Long‐term chemotherapy impact should be discussed with patients in a shared‐decision making process and approaches to symptom management during survivorship care are needed.

Funder

Cancer Prevention and Research Institute of Texas

Susan G. Komen

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Reference58 articles.

1. Breast cancer statistics, 2019

2. American Cancer Society.Cancer facts and figures 2019–2020.2019–2020https://www.cancer.org/content/dam/cancer‐org/research/cancer‐facts‐and‐statistics/breast‐cancer‐facts‐and‐figures/breast‐cancer‐facts‐and‐figures‐2019‐2020.pdf

3. American Cancer Society.Cancer treatment & survivorship facts & figures 2019–2021. Accessed November 11 2021.https://www.cancer.org/content/dam/cancer‐org/research/cancer‐facts‐and‐statistics/cancer‐treatment‐and‐survivorship‐facts‐and‐figures/cancer‐treatment‐and‐survivorship‐facts‐and‐figures‐2019‐2021.pdf

4. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

5. Adjuvant Chemotherapy in Older and Younger Women With Lymph Node–Positive Breast Cancer

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3